Silvius Stephens*
Chronic inflammation is a key driver of cardiac diseases. This article reviews recent developments in anti-inflammatory therapies, including IL-1β inhibitors and colchicine, which have shown efficacy in reducing cardiovascular events in patients with a history of myocardial infarction. Cardiovascular disease remains the leading cause of mortality worldwide, with coronary artery disease and heart failure being significant contributors. While traditional risk factors such as hypertension, diabetes, and dyslipidemia are well-established in the pathogenesis of these conditions, mounting evidence suggests that inflammation plays a pivotal role in the initiation and progression of cardiac diseases.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 